Sputum test to guide individualized drug-resistant TB treatment
Part of Infections clinical trials.
This trial tests whether using results from a detailed sputum (phlegm) test to tailor treatment improves outcomes in people with drug-resistant (rifampicin-resistant) pulmonary TB. It may help you get the most appropriate regimen based on your specific test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and newly diagnosed with pulmonary TB based on a culture or Xpert/Ultra test
- Your test shows rifampicin resistance using the GeneXpert test
- You started TB treatment 7 days or less ago
- You can give written consent and are willing to attend regular study visits
- You are not currently in MDR-TB treatment after completing 7 days (the study is for very early treatment)
- You are not pregnant or breast-feeding (or, if this applies, you must be willing to stop) and not planning pregnancy during the treatment period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This study uses next-generation gene testing to help manage active drug-resistant tuberculosis. It may help doctors choose the most appropriate treatment by better identifying the TB’s drug resistance.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This trial is for people newly diagnosed with tuberculosis (TB) and looks at how TB bacteria can become resistant to multiple drugs. It will help doctors understand which treatments work best for new TB patients.
This study tests rapid TB screening and lab-style diagnostic methods to see how well they find TB disease and TB that is resistant to rifampin (a key TB drug). It may help doctors diagnose TB faster and more accurately, especially in people at higher risk.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
Hear when a new Tuberculosis, Multidrug-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.